4,901 trials
Neoplasms
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 1; 0; 0 participants
Breast Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 24; 11 participants
Coronary Artery Disease
Primary: Change in Maximum Platelet Aggregation (MPA) to 20 Micromoles (μM) Adenosine Diphosphate (ADP) as Measured by Light Transmission Aggregometry (LTA) From Baseline to 12…
Neoplasms · Malignant
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Human Immunodeficiency Virus Type 1 (HIV-1) · HIV Infections
Primary: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Cmin) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without…
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve Within a Dosing Interval at Steady-State (AUCss) for Sulfamethoxazole — 786; 909 h*ug/ml
Osteoporosis, Postmenopausal
Primary: Part A - Cumulative Skin Irritation by Draize Score — 299; 40; 146; 390 patches with Draize scores
Chronic Hepatitis C
Primary: Cmax (Maximum Observed Concentration in Plasma) of MP-424 — 2.24; 3.34; 3.68 μg / mL
Choroidal Neovascularization
Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…
Pulmonary Sarcoidosis · Lung Function
Primary: Change in Absolute FVC From Baseline to Post Completion of 8 Weeks of Antibiotic Therapy. — 2.61 liters
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Healthy
Primary: Chronic Modulation of Cerebral Blood Flow — 0; 0 Participants — p=>0.05
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Number of Participants Who Experienced at Least One Adverse Event — 1; 1; 0; 1 participants
Rubeosis Iridis · Proliferative Diabetic Retinopathy
Primary: Adverse Event (AE) — 0 participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Prasugrel's Active Metabolite R-138727 During Loading Dose — 600; 283 nanogram times hour/milliliter…